Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

Steroid-refractory Acute Graft-versus-host Disease Clinical Trial

— BALDER  

Official title:

A Randomised, Open-label, Controlled, Multicentre, Phase 2 Trial of First-line Treatment With Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Paediatric Participants With Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation (BALDER Trial)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06075706
• Other study ID #: MC-MSC.2/aGvHD
• Secondary ID: 2023-503952-28-0
• Status: Recruiting
• Phase: Phase 2
• Start date: November 13, 2023
• Est. completion date: June 2031

Study information

• Verified date: June 2024
• Source: medac GmbH
• Contact: Medac Clinical Trial Information
• Phone: +49 (0)4103 8006
• Email: ClinicalTrialInformation[@]medac.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is the comparative evaluation of overall response rate (ORR) in paediatric participants with steroid-refractory acute graft-versus-host disease (SR-aGvHD) at Visit Day 28 after treatment with MC0518 or first used best available therapy (BAT).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: June 2031
• Est. primary completion date: August 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 28 Days to 17 Years

Eligibility

Inclusion Criteria:

1. Participant had a previous allogeneic HSCT as indicated for non-malignant (including inborn errors of metabolism, primary immunodeficiencies, haemoglobinopathies, and bone marrow failure syndromes) or hematological malignant disease or neuroblastoma.

2. Participant has been clinically diagnosed with Grade II to IV aGvHD according to Harris et al. A biopsy of the involved organs with aGvHD is encouraged but not required.

3. Participant has experienced failure of previous first-line aGvHD treatment (that is, SR-aGvHD), defined as:

• aGvHD progression within 3 to 5 days of therapy onset with >=2 milligram per kilogram per day (mg/kg/day) of prednisone equivalent or

• failure to improve within 5 to 7 days of treatment initiation with >=2 mg/kg/day of prednisone equivalent or

• incomplete response after greater than (>) 28 days of immunosuppressive treatment including at least 5 days with >=2 mg/kg/day of prednisone equivalent.

4. Male or female participant who is >=28 days and <18 years of age and has a minimum body weight of 3.2 kilograms (kg) at the Screening Visit.

5. Participant has an estimated life expectancy of >28 days.

6. Participant, if female and of childbearing potential, agrees to use a highly effective contraceptive measure starting at the Screening Visit and continuing throughout the entire trial period.

7. Participant, if a fertile male, agrees to sexual abstinence or to use a condom during sexual activity with their female partner of childbearing potential or pregnant partner. Additionally, if their partner is a woman of childbearing potential (WOCBP), then their partner must use an additional highly effective contraceptive method during sexual activity starting at the Screening Visit and continuing throughout the entire trial period.

8. A written informed consent of the participant's parent(s) / legal guardian(s) (and participant's assent, when applicable) has been obtained according to national regulations.

Exclusion Criteria:

1. Participant has overt relapse or progression or persistence of the underlying disease.

2. Participant has received the last HSCT for a solid tumor disease other than neuroblastoma.

3. Participant has graft-versus-host disease overlap syndrome.

4. Participant has received systemic first-line treatment for aGvHD other than steroids and a prophylaxis with other than calcineurin inhibitors, mammalian target of rapamycin (mTOR) inhibitors, anti-thymocyte globulin, mycophenolate mofetil, methotrexate, abatacept, or cyclophosphamide. Note: In vitro or in vivo graft manipulation to prevent graft-versus-host disease (example, T-cell depletion) during HSCT is permitted. Restart of initial prophylaxis with calcineurin inhibitors, mammalian target of rapamycin inhibitors, or mycophenolate mofetil after aGvHD onset is permitted.

5. Participant has received prior mesenchymal stromal cell (MSC) treatment, including MC0518/Obnitix®.

6. Participant has a known pregnancy (as confirmed by a positive pregnancy test result at the Screening Visit) and / or is breastfeeding.

7. Participant has a known hypersensitivity to MC0518 and / or its excipients (dimethyl sulfoxide, human serum albumin, isotonic sodium chloride solution).

8. Participant has a known hypersensitivity or any contraindication to the Investigator's choice BAT (extracorporeal photopheresis, anti thymocyte globulin, etanercept, infliximab, or ruxolitinib) and / or its excipients. For a list of excipients please refer to the respective Summary of Product Characteristics.

9. Participant has an underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the participant.

10. Participant has an uncontrolled infection (examples, sepsis or multi-organ failure) including significant bacterial, fungal, viral, or parasitic infection requiring treatment.

11. Participant has received treatment with any other investigational agent within 30 days or 5 half-lives (whichever is longer) before the Screening Visit.

Related Conditions & MeSH terms

• Graft vs Host Disease
• Steroid-refractory Acute Graft-versus-host Disease

Intervention

Biological:
• MC0518
MC0518 will be intravenously infused immediately after thawing.
• BAT
BAT including ECP, ATG, etanercept, infliximab or RUX will be administered based on Investigator's decision.

Locations

Country	Name	City	State
France	CHU de Bordeaux - Hopital des Enfants	Bordeaux
France	CHU Grenoble Alpes - Hopital Couple Enfant (HCE)	La Tronche
France	Centre Hospitalier Universitaire de Lille CHU Lille - Hopital Jeanne de Flandre HJF	Lille
France	Institut d'Hematologie et d'Oncologie Pediatrique (IHOPe)	Lyon
France	CHU de Marseille-Hopital de la Timone	Marseille
France	Centre Hospitalier Regional Universitaire (CHRU) Montpellier - hopital Arnaud de Villeneuve	Montpellier
France	CHU de Nantes - Hopital Mere Enfant	Nantes Cedex 01
France	Hopital Robert Debre	Paris
France	CHU Rennes - Hopital Pontchaillou	Rennes
France	CHU de Rouen - Hopital Charles Nicolle	Rouen
France	CHRU de Strasbourg - Hopital de Hautepierre	Strasbourg
France	CHRU Nancy, Hopitaux de Brabois	Vandoeuvre-les-Nancy
Germany	Uniklinik RWTH Aachen, Klinik fur Kinder- und Jugendmedizin	Aachen
Germany	Universitatsklinikum Dusseldorf	Dusseldorf
Germany	Universitaetsklinikum Essen	Essen
Germany	Klinikum der Johann Wolfgang Goethe	Frankfurt
Germany	Universitaetsklinikum Freiburg - Zentrum fuer Kinder- und Jugendmedizin (ZKJ)	Freiburg
Germany	Justus-Liebig-Universitaet Giessen	Giessen
Germany	Medizinische Hochschule Hannover MHH	Hannover
Germany	Department of Pediatrics, Jena University Hospital	Jena
Germany	Universitaetsklinikum Leipzig - Abteilung fuer Paediatrische Onkologie, Haematologie und Haemostaseologie	Leipzig
Germany	Universitaetsklinikum Muenster (UKM) - Klinik fuer Kinder- und Jugendmedizin - Paediatrische Haematologie und Onkologie	Muenster
Italy	IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola Malpighi	Bologna
Italy	Pediatric Clinic Onco Hematology San Gerardo Hospital	Monza
Italy	U.O.C. Oncoematologia Pediatrica, Fondazione IRCCS Policlinico San Matteo	Pavia
Italy	Hematology and Cellular Therapy Ospedale Bambino Gesu	Rome
Italy	A.O.U. Citta della Salute e della Scienza di Torino Ospedale Infantile Regina Margherita	Turin
Poland	Dzieciecy Szpital Kliniczny im. A.Gebali w Lublinie	Lublin
Poland	Szpital Kliniczny im. Karola Jonschera UM	Poznan
Poland	Department of Pediatric Hematology, Oncology and BMT, Wroclaw Medical University	Wroclaw	Dolnoslaskie
Spain	Hospital Sant Joan de Deu Barcelona (HSJDB)	Barcelona
Spain	Hospital Universitario Vall dHebron	Barcelona
Spain	Hospital Infantil Universitario La Paz	Madrid
Spain	Hospital Niño Jesus	Madrid
Spain	Instituto de Investigacion Biomedica de Malaga IBIMA - sede Hospital Regional Universitario de Malaga HRUM Hospital Carlos Haya	Malaga
Spain	Instituto Murciano de Investigacion Biosanitaria (IMIB) Virgen de la Arrixaca	Murcia
Spain	Clinica Universitaria de Navarra	Pamplona	Navarra
Spain	Hospital Universitari I politecnic La Fe Jose	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
medac GmbH

Countries where clinical trial is conducted

France,  Germany,  Italy,  Poland,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Overall Response (OR)	OR is defined as complete response (CR) or partial response (PR) at Day 28 relative to acute graft-versus-host disease (aGvHD) status at baseline. CR is defined as resolution of aGvHD in all involved organs. PR is defined as improvement in 1 stage in at least 1 or more organs involved with aGvHD symptoms without progression in others.	At Day 28
Secondary	Number of Participants With Freedom From Treatment Failure (FFTF) Until 6 Months (Day 180)	FFTF is defined as the time from the date of randomization to the date of the event. An event is defined as death, relapse or progression of the underlying disease, or addition or change to any further systemic immunosuppressive aGvHD therapy.	Up to 6 months (Day 180)
Secondary	Overall Survival (OS)	Overall survival is defined as the time from randomization to the date of death due to any cause.	Up to Month 24
Secondary	Number of Participants With aGvHD Response	aGvHD response will be categorized as OR (CR + PR), CR, PR, and NR. NR is defined as the absence of CR or PR.	At Days 28, 60, 100 and 180
Secondary	Change From Baseline in aGvHD Grades	aGvHD grades: Grade 0- no organ involvement (that is, Stage 0 skin, Stage 0 liver, and Stage 0 gastrointestinal [GI]); Grade I-Stage 1 - 2 skin without liver/GI involvement; Grade II- Stage 3 skin and / or Stage 1 liver and / or Stage 1 GI; Grade III- Stage 2 - 3 liver and / or Stage 2 - 3 GI; Grade IV- Stage 4 skin and / or Stage 4 liver and/or Stage 4 GI.	Baseline, Days 8, 15, 22, 28, 60, 100 and 180
Secondary	Time to Response	Time to response is defined as the time from the date of the first treatment administration to the date of response (CR or PR).	From the date of the first treatment administration to the date of the first response (CR or PR) (up to 5 years)
Secondary	Duration of Response	Duration is defined as the time from the date of the first OR (CR or PR) to the date of aGvHD assessed as NR compared to the baseline assessment, or the date of addition of or change to any further systemic aGvHD therapy (except changes in steroid treatment), in responders.	Up to Month 24
Secondary	Number of Participants With Best Overall Response (OR)	Best OR is defined as the achievement of an OR at any time point up to and including Day 28.	Up to Day 28
Secondary	Cumulative Dose of Steroids for SR-aGvHD per Kilogram (kg) of Body Weight	The cumulative dose of steroids given for SR-aGvHD per kg of body weight from the date of the first treatment administration until Day 28, Day 60, and until Visit Month 24 will be analyzed.	From the date of the first treatment administration up to Day 28, Day 60, and Month 24
Secondary	Number of Participants With Chronic Graft-versus-host Disease (cGvHD)	Number of participants with cGvHD will be reported.	From Day 60 up to Month 24
Secondary	Time to Chronic Graft-versus-host Disease (cGvHD)	Time to cGvHD is defined as the time between the last day of hematopoietic stem cell transplantation (HSCT) to the first episode of cGvHD.	From Day 60 up to Month 24
Secondary	Number of Participants With Graft Failure (GF)	Number of participants with GF will be reported.	Baseline up to Month 24
Secondary	Number of Participants With Relapse or Progression in Participants With Underlying Malignant Disease	Number of participants with relapse or progression in participants with underlying malignant disease will be reported.	From randomization up to Month 24
Secondary	Time to Relapse or Progression in Participants With Underlying Malignant Disease	Time to relapse or progression is defined as the time from the date of randomization to the date of relapse or progression until Month 24.	From randomization up to Month 24
Secondary	Event-free Survival (EFS)	EFS is defined as the time from the date of randomization to the date of the event. An event is defined as GF, relapse or progression of the underlying disease, or death due to any cause.	From the date of randomization to date of GF, relapse or progression of the underlying disease, or death due to any cause, whichever occurs first (up to Month 24)
Secondary	Non-relapse Mortality (NRM)	NRM is defined as the time from the date of randomization to the date of the event. An event is defined as death without previous relapse or progression of the underlying disease.	From the date of randomization to the date of death without previous relapse or progression of the underlying disease (up to Month 24)
Secondary	Number of Participants With Adverse Events (AEs)	An AE is defined as any untoward medical occurrence in a trial participant administered a trial treatment that does not necessarily have a causal relationship with this trial treatment.	Up to Month 24
Secondary	Number of Participants With Adverse Reactions (ARs) by Severity	An AR is defined as all noxious and unintended responses to a trial treatment related to any dose administered / procedure performed. Severity will be graded based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening consequences; urgent intervention indicated; Grade 4- Death related to the AE.	Up to Month 24
Secondary	Change From Baseline in Performance Score Based on Karnofsky Scale	The Karnofsky performance score (KPS), which is reported on an ordinal scale from 0 to 100, provides a rough measure of the participant's (recipient age greater than or equal to [>=] 16 years) well-being, including their ability to conduct activities of daily living and functional capacity. Higher score indicates normal, no complaints and no evidence of disease.	Baseline, Days 8, 15, 22, 28, 60 and 100
Secondary	Change From Baseline in Performance Score Based on Lansky Scale	A Lansky score (recipient age >=1 year and less than [<] 16 years) will be recorded pre-treatment and measured serially at regular intervals after treatment. The score is a standard performance score that measures overall function of the child with a scale range from 0 to 100. Higher score indicates full activeness.	Baseline, Days 8, 15, 22, 28, 60 and 100
Secondary	Pediatric Quality of Life Inventory (PedsQL™) 4.0 Generic Core Scale Score	The PedsQL Generic Core Scales instrument is a standardized, established, and validated questionnaire in pediatric populations that systematically assesses the participants' and parents' / legal guardians' perceptions of health-related quality of life (HRQoL). The Generic Core Scales module consists of 23 items measuring the core dimensions of health on physical, emotional, social, and school functioning that can be used for self- and proxy-reports in age groups ranging from 2 to 18 years (child self-report ages: 5 to 7, 8 to 12, 13 to 18; parent-proxy report ages: 2 to 4, 5 to 7, 8 to 12, 13 to 18). The scores of this questionnaire range from 0 to 100 , where higher scores indicate better HRQoL.	Baseline, Days 28, 60, 100 and 180
Secondary	Change From Baseline in PedsQL™ Stem Cell Transplant Module Scale Score	The PedsQL™ Stem Cell Transplant Module is a disease-specific module of the PedsQL™ for toddlers (2 to 4 years of age), young children (5 to 7 years of age), children (8 to 12 years of age), and adolescents (13 to 18 years of age) and was designed to measure the quality of life in participants undergoing stem cell transplantation. It consists of the following HRQoL domains: pain and hurt, fatigue / sleeping problems / weakness, nausea, worry / anxiety about disease / treatment, nutritional problems, neurocognitive problems, communication about disease / treatment, loneliness, physical functioning and additional somatic complaints (pruritus, skin inflammation, oral problems, eyes or breathing) including patients' and parents' assessment. The scores of this disease-specific module of the PedsQL™ range from 0 to 100, where higher scores indicate better HRQoL.	Baseline, Days 28, 60, 100 and 180